Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Poxel SA
POXELCurrent price
0.28 EUR
-0.002 EUR (-0.70%)
Last closed
0.28 EUR
Company
www.poxelpharma.com
ISIN
FR0012432516
Sector
Healthcare
Industry
Biotechnology
Exchange
Euronext Paris
Capitalization
15 026 511 EUR
Yield for 12 month
-28.15 %
1Y
3Y
5Y
10Y
15Y
POXEL
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial dysfunction; and Sumitomo Pharma for development and commercialization of Imeglimin. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France. Address: Immeuble Le Sunway, Lyon, France, 69007
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
3.22 EURP/E ratio
–Dividend Yield
–Current Year
+1 981 000 EUR
Last Year
+674 000 EUR
Current Quarter
+1 026 000 EUR
Last Quarter
+955 000 EUR
Current Year
+1 000 EUR
Last Year
+2 000 EUR
Current Quarter
+1 001 EUR
Last Quarter
-16 922 000 EUR
Key Figures POXEL
1 year
3 years
5 years
10 years
EBITDA
-11 989 000 EUR
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-90.94 %
PEG Ratio
–
Return On Equity TTM
-323.37 %
Wall Street Target Price
3.22 EUR
Revenue TTM
1 981 000 EUR
Book Value
-1.27 EUR
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
73.6 %
Dividend Yield
–
Gross Profit TTM
13 338 000 EUR
Earnings per share
-1.05 EUR
Diluted Eps TTM
-1.05 EUR
Most Recent Quarter
IV 2023
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics POXEL
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History POXEL
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation POXEL
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
30.1855
Price Sales TTM
7.5853
Enterprise Value EBITDA
-1.5511
Price Book MRQ
5.3442
Financials POXEL
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators POXEL
For 52 weeks
0.27 EUR
0.9 EUR
50 Day MA
0.45 EUR
Shares Short Prior Month
–
200 Day MA
0.53 EUR
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart